Parkinson's Disease

Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders: Second Edition

Volumn , Issue , 2011, Pages 194-223

  Jellinger, Kurt A ^a  

^a INSTITUTE OF CLINICAL NEUROBIOLOGY   (Austria)

Author keywords

synuclein; Clinical features; Differential diagnosis; Etiopathogenesis; Lewy bodies; Neuropathology; Parkinson's disease; Parkinsonism; Pathophysiology

Indexed keywords

EID: 84871908009     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444341256.ch21     Document Type: Chapter

References (263)

1. 1 Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet 2009; 373: 2055-2066.
2. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008; 79: 368-376.
3. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56: 33-39.
4. Litvan I, Bhatia KP, Burn DJ et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 2003; 18: 467-486.
5. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125: 861-870.
6. Dickson DW, Braak H, Duda JE et al. Diagnostic criteria for the neuropathological assessment of Parkinson disease: report of the Neuropathology and Genetics Working Group of the Second International Brainstorming Conference on Parkinson disease. Lancet Neurol 2009; 8: 1150-1157.
7. Jellinger KA. Lewy body disorders. In: Youdim MBH, Riederer P, Mandel SA, Battistin L, Lajtha A (eds) Degenerative Diseases of the Nervous System. New York: Springer Science, 2007, pp. 267-343.
8. Shulman JM, De Jager PL, Feany MB. Parkinson's disease: genetics and pathogenesis. Annu Rev Pathol 2011; 6: 193-222.
9. Shen WB, McDowell KA, Siebert AA, et al. Environmental neurotoxin-induced progressive model of parkinsonism in rats. Ann Neurol 2010; 68: 70-80.
10. Olanow CW, Kordower JH. Modeling Parkinson's disease. Ann Neurol 2009; 66: 432-436.
11. Meredith GE, Sonsalla PK, Chesselet MF. Animal models of Parkinson's disease progression. Acta Neuropathol 2008; 115: 385-398.
12. Kempster PA, Hurwitz B, Lees AJ. A new look at James Parkinson's Essay on the Shaking Palsy. Neurology 2007; 69: 482-485.
13. Lewy FH. Zur pathologischen Anatomie der Paralysis agitans. D Z Nervenheilk 1913; 50: 50-55.
14. Trétiakoff MC. Contributionàl'étude de l'anatomie pathologique du locus niger de Soemmering. Universitéde Paris, 1919.
15. Cantuti-Castelvetri I, Keller-McGandy C, Bouzou B et al. Effects of gender on nigral gene expression and parkinson disease. Neurobiol Dis 2007; 26: 606-614.
16. Alves G, Forsaa EB, Pedersen KF, Dreetz Gjerstad M, Larsen JP. Epidemiology of Parkinson's disease. J Neurol 255 Suppl 2008; 5: 18-32.
17. Yacoubian TA, Howard G, Kissela B, Sands CD, Standaert DG. Racial differences in Parkinson's disease medication use in the reasons for geographic and racial differences in stroke cohort: a cross-sectional study. Neuroepidemiology 2009; 33: 329-334.
18. Dorsey ER, Constantinescu R, Thompson JP et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007; 68: 384-386.
19. Alladi PA, Mahadevan A, Yasha TC, Raju TR, Shankar SK, Muthane U. Absence of age-related changes in nigral dopaminergic neurons of Asian Indians: relevance to lower incidence of Parkinson's disease. Neuroscience 2009; 159: 236-245.
20. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006; 5: 525-535.
21. Perez F, Helmer C, Dartigues JF, Auriacombe S, Tison F. A 15-year population-based cohort study of the incidence of Parkinson's Disease and dementia with Lewy bodies in an elderly French cohort. J Neurol Neurosurg Psychiatry 2010; 81: 742-746.
22. Diem-Zangerl A, Seppi K, Wenning GK et al. Mortality in Parkinson's disease: a 20-year follow-up study. Mov Disord 2009; 24: 819-825.
23. Bekris LM, Mata IF, Zabetian CP. The genetics of Parkinson disease. J Geriatr Psychiatry Neurol 2010; 23: 228-242.
24. Klein C. Genetics of Parkinson's disease-an overview. In: Schapira AHV, Lang AET, Fahn S (eds) Movement Disorders 4. Philadelphia: Elsevier Saunders, 2010, pp. 15-39.
25. Polymeropoulos MH, Lavedan C, Leroy E et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045-2047.
26. Krüger R, Kuhn W, Müller T et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998; 18: 106-108.
27. Kitada T, Asakawa S, Hattori N et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392: 605-608.
28. Matsumine H, Saito M, Shimoda-Matsubayashi S et al. Localization of a gene for an autosomal recessive form of juvenile Parkinsonism to chromosome 6q25.2-27. Am J Hum Genet 1997; 60: 588-596.
29. Hattori N, Kitada T, Matsumine H et al. Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the Parkin gene in affected individuals. Ann Neurol 1998; 44: 935-941.
30. Lücking CB, Abbas N, Dürr A et al. Homozygous deletions in parkin gene in European and North African families with autosomal recessive juvenile parkinsonism. The European Consortium on Genetic Susceptibility in Parkinson's Disease and the French Parkinson's Disease Genetics Study Group. Lancet 1998; 352: 1355-1356.
31. Gasser T, Müller-Myhsok B, Wszolek ZK et al. A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nature Genetics 1998; 18: 262-265.
32. Wszolek ZK, Pfeiffer B, Fulgham JR et al. Western Nebraska family (family D) with autosomal dominant parkinsonism. Neurology 1995; 45: 502-505.
33. Singleton AB, Farrer M, Johnson J et al. Alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003; 302: 841.
34. Farrer M, Gwinn-Hardy K, Muenter M et al. A chromosome 4p haplotype segregating with Parkinson's disease and postural tremor. Hum Mol Genet 1999; 8: 81-85.
35. Leroy E, Boyer R, Auburger G et al. The ubiquitin pathway in Parkinson's disease. Nature 1998; 395: 451-452.
36. Valente EM, Bentivoglio AR, Dixon PH et al. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am J Hum Genet 2001; 68: 895-900.
37. Valente EM, Abou-Sleiman PM, Caputo V et al. Hereditary earlyonset Parkinson's disease caused by mutations in PINK1. Science 2004; 304: 1158-1160.
38. Bonifati V, Rizzu P, van Baren MJ et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003; 299: 256-259.
39. van Duijn CM, Dekker MC, Bonifati V et al. Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. Am J Hum Genet 2001; 69: 629-634.
40. Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 2002; 51: 296-301.
41. Zimprich A, Biskup S, Leitner P et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004; 44: 601-607.
42. Paisán-Ruiz C, Jain S, Evans EW et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004; 44: 595-600.
43. Ramirez A, Heimbach A, Gründemann J et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nature Genetics 2006; 38: 1184-1191.
44. Ning YP, Kanai K, Tomiyama H et al. PARK9-linked parkinsonism in eastern Asia: mutation detection in ATP13A2 and clinical phenotype. Neurology 2008; 70: 1491-1493.
45. Haugarvoll K, Toft M, Skipper L et al. Fine-mapping and candidate gene investigation within the PARK10 locus. Eur J Hum Genet 2009; 17: 336-343.
46. Hicks AA, Pétursson H, Jónsson T et al. A susceptibility gene for late-onset idiopathic Parkinson's disease. Ann Neurol 2002; 52: 549-555.
47. Lautier C, Goldwurm S, Dürr A et al. Mutations in the GIGYF2 (TNRC15) Gene at the PARK11 Locus in Familial Parkinson Disease. Am J Hum Genet 2008; 82: 822-833.
48. Sutherland GT, Siebert GA, Newman JR et al. Haplotype analysis of the PARK 11 gene, GIGYF2, in sporadic Parkinson's disease. Mov Disord 2009; 24: 449-452.
49. Di Fonzo A, Dekker MC, Montagna P et al. FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome. Neurology 2009; 72: 240-245.
50. Pankratz N, Nichols WC, Uniacke SK et al. Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations. Am J Hum Genet 2002; 71: 124-135.
51. Scott WK, Nance MA, Watts RL et al. Complete genomic screen in Parkinson disease: evidence for multiple genes. Jama 2001; 286: 2239-2244.
52. Sina F, Shojaee S, Elahi E, Paisán-Ruiz C. R632W mutation in PLA2G6 segregates with dystonia-parkinsonism in a consanguineous Iranian family. Eur J Neurol 2009; 16: 101-104.
53. Paisán-Ruiz C, Bhatia KP, Li A et al. Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol 2009; 65: 19-23.
54. Clark LN, Kartsaklis LA, Wolf Gilbert R et al. Association of glucocerebrosidase mutations with dementia with Lewy bodies. Arch Neurol 2009; 66: 578-583.
55. Shojaee S, Sina F, Banihosseini SS et al. Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays. Am J Hum Genet 2008; 82: 1375-1384.
56. Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 2004; 351: 1972-1977.
57. Mata IF, Samii A, Schneer SH et al. Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. Arch Neurol 2008; 65: 379-382.
58. Neumann J, Bras J, Deas E et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 2009; 132: 1783-1794.
59. DePaolo J, Goker-Alpan O, Samaddar T, Lopez G, Sidransky E. The association between mutations in the lysosomal protein glucocerebrosidase and parkinsonism. Mov Disord 2009; 24: 1571-1578.
60. Sidransky E, Nalls MA, Aasly JO et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009; 361: 1651-1661.
61. Goto S, Lee LV, Munoz EL et al. Functional anatomy of the basal ganglia in X-linked recessive dystonia-parkinsonism. Ann Neurol 2005; 58: 7-17.
62. Lee MS, Kim YD, Im JH, Kim HJ, Rinne JO, Bhatia KP. 123I-IPT brain SPECT study in essential tremor and Parkinson's disease. Neurology 1999; 52: 1422-1426.
63. Tobin JE, Latourelle JC, Lew MF et al. Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study. Neurology 2008; 71: 28-34.
64. Wider C, Dickson DW, Stoessl AJ et al. Pallidonigral TDP-43 pathology in Perry syndrome. Parkinsonism Relat Disord 2009; 15: 281-286.
65. Wider C, Dachsel JC, Farrer MJ, Dickson DW, Tsuboi Y, Wszolek ZK. Elucidating the genetics and pathology of Perry syndrome. J Neurol Sci 2010 289: 149-154.
66. Shan DE, Liu RS, Sun CM, Lee SJ, Liao KK, Soong BW. Presence of spinocerebellar ataxia type 2 gene mutation in a patient with apparently sporadic Parkinson's disease: clinical implications. Mov Disord 2004 19: 1357-1360.
67. Yomono HS, Kurisaki H, Hebisawa A, Sakiyama Y, Saito Y, Murayama S. Autopsy case of SCA2 with Parkinsonian phenotype. Rinsho Shinkeigaku 2010; 50: 156-162.
68. Gasser T. Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Rev Mol Med 2009; 11: e22.
69. Dawson TM, Ko HS, Dawson VL. Genetic animal models of Parkinson's disease. Neuron 2010; 66: 646-661.
70. Hardy J, Lewis P, Revesz T, Lees A, Paisán-Ruiz C. The genetics of Parkinson's syndromes: a critical review. Curr Opin Genet Dev 2009; 19: 254-265.
71. Bras JM, Singleton A. Genetic susceptibility in Parkinson's disease. Biochim Biophys Acta 2009; 1792: 597-603.
72. Ibañez P, Lesage S, Janin S et al. Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms. Arch Neurol 2009; 66: 102-108.
73. Klein C, Schneider SA, Lang AE. Hereditary parkinsonism: Parkinson disease look-alikes-an algorithm for clinicians to "PARK" genes and beyond. Mov Disord 2009; 24: 2042-2058.
74. Nishioka KMP, KefiMM, Jasinska-Myga BMP et al. A comparative study of LRRK2, PINK1 and genetically undefined familial Parkinson disease. J Neurol Neurosurg Psychiatry 2010; 81: 391-395.
75. Markopoulou K, Dickson DW, McComb RD et al. Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson's disease. Acta Neuropathol 2008; 116: 25-35.
76. Farrer M, Kachergus J, Forno L et al. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol 2004; 55: 174-179.
77. Seidel K, Schöls L, Nuber S et al. First appraisal of brain pathology owing to A30P mutant alpha-synuclein. Ann Neurol 2010; 67: 684-689.
78. Samaranch L, Lorenzo-Betancor O, Arbelo JM et al. PINK1-linked parkinsonism is associated with Lewy body pathology. Brain 2010; 133: 1128-1142.
79. Healy DG, Falchi M, O'Sullivan SS et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008; 7: 583-590.
80. Dächsel JC, Farrer MJ. LRRK2 and Parkinson disease. Arch Neurol (2010; 67: 542-547.
81. Simunovic F, Yi M, Wang Y et al. Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology. Brain 2009; 132: 1795-1809.
82. Tsuboi Y, Dickson DW, Nabeshima K et al. Neurodegeneration involving putative respiratory neurons in Perry syndrome. Acta Neuropathol 2008; 115: 263-268.
83. Farrer MJ, Hulihan MM, Kachergus JM et al. DCTN1 mutations in Perry syndrome. Nat Genet 2009; 41: 163-165.
84. Goker-Alpan O, Lopez G, Vithayathil J, Davis J, Hallett M, Sidransky E. The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch Neurol 2008; 65: 1353-1357.
85. Goker-Alpan O, Stubblefield BK, Giasson BI, Sidransky E. Glucocerebrosidase is present in alpha-synuclein inclusions in Lewy body disorders. Acta Neuropathol 2010; 120: 641-649.
86. Lesage S, Anheim M, Condroyer C et al. Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. Hum Mol Genet 2011; 20: 202-210.
87. Mitsui J, Mizuta I, Toyoda A et al. Mutations for Gaucher disease confer high susceptibility to Parkinson disease. Arch Neurol 2009; 66: 571-576.
88. Ron I, Rapaport D, Horowitz M. Interaction between parkin and mutant glucocerebrosidase variants: a possible link between Parkinson disease and Gaucher disease. Hum Mol Genet 2010; 19: 3771-3781.
89. Cookson MR, Hardy J, Lewis PA. Genetic neuropathology of Parkinson's disease. Int J Clin Exp Pathol 2008; 1: 217-231.
90. Simón-Sánchez J, Schulte C, Bras JM et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009; 41: 1308-1312.
91. Rodriguez-Oroz MC, Jahanshahi M, Krack P et al. Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol 2009; 8: 1128-1139.
92. Tolosa E, Santamaria J, Gaig C, Compta Y. Nonmotor aspects of Parkinson's disease. In: Schapira AHV, Lang AET, Fahn S (eds) Movement Disorders 4. Philadelphia: Saunders-Elsevier, 2010, pp. 229-251.
93. Ponsen MM, Stoffers D, Twisk JW, Wolters E, Berendse HW. Hyposmia and executive dysfunction as predictors of future Parkinson's disease: a prospective study. Mov Disord 2009; 24: 1060-1065.
94. Savica R, Rocca WA, Ahlskog JE. When does Parkinson disease start? Arch Neurol 2010; 67: 798-801.
95. Jellinger KA, Mizuno Y. Parkinson disease. In: Dickson DW (ed) Neurodegeneration: the Molecular Pathology of Dementia and Movement Disorders. Basel: ISN Neuropath Press, 2003, pp. 159-187.
96. Maetzler W, Liepelt I, Berg D. Progression of Parkinson's disease in the clinical phase: potential markers. Lancet Neurol 2009; 8: 1158-1171.
97. Chaudhuri KR, Tolosa E, Schapira A, Poewe W. Non-Motor Symptoms of Parkinson's Disease. Oxford: Oxford University Press, 2009.
98. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837-844.
99. Elgh E, Domellöf M, Linder J, Edström M, Stenlund H, Forsgren L. Cognitive function in early Parkinson's disease: a population-based study. Eur J Neurol 2009; 16: 1278-1284.
100. Aarsland D, Brønnick K, Ehrt U et al. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 2007; 78: 36-42.
101. Postuma RB, Gagnon JF, Vendette M, Montplaisir JY. Idiopathic REM sleep behavior disorder in the transition to degenerative disease. Mov Disord 2009; 24: 2225-2232.
102. Postuma RB, Gagnon JF, Vendette M, Charland K, Montplaisir J. Manifestations of Parkinson disease differ in association with REM sleep behavior disorder. Mov Disord 2008; 23: 1665-1672.
103. Lim SY, Lang AE. The nonmotor symptoms of Parkinson's disease -an overview. Mov Disord 25 Suppl 2010; 1: S123-130.
104. Rajput AH, Voll A, Rajput ML, Robinson CA, Rajput A. Course in Parkinson disease subtypes: A 39-year clinicopathologic study. Neurology 2009; 73: 206-212.
105. Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ. A clinico-pathological study of subtypes in Parkinson's disease. Brain 2009; 132: 2947-2957.
106. Benninger DH, Thees S, Kollias SS, Bassetti CL, Waldvogel D. Morphological differences in Parkinson's disease with and without rest tremor. J Neurol 2009; 256: 256-263.
107. Martin WRW, Wieler M, Gee M, Camicioli R. Temporal lobe changes in early, untreated Parkinson's disease. Mov Disord 2009; 24: 1949-1954.
108. Michaeli S, Oz G, Sorce DJ et al. Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts. Mov Disord 2007; 22: 334-340.
109. Hotter A, Esterhammer R, Schocke MF, Seppi K. Potential of advanced MR imaging techniques in the differential diagnosis of parkinsonism. Mov Disord 2009; 24 Suppl 2: S711-720.
110. Rizzo G, Martinelli P, Manners D et al. Diffusion-weighted brain imaging study of patients with clinical diagnosis of corticobasal degeneration, progressive supranuclear palsy and Parkinson's disease. Brain 2008; 131: 2690-2700.
111. Vaillancourt DE, Spraker MB, Prodoehl J et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 2009; 72: 1378-1384.
112. Mahlknecht P, Hotter A, Hussl A, Esterhammer R, Schocke M, Seppi K. Significance of MRI in diagnosis and differential diagnosis of Parkinson's disease. Neurodegener Dis 2010; 7: 300-318.
113. Tang CC, Poston KL, Eckert T et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol 2010; 9: 149-158.
114. Brooks DJ. Imaging approaches to Parkinson disease. J Nucl Med 2010; 51: 596-609.
115. Nandhagopal R, Kuramoto L, Schulzer M et al. Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain 2009; 132: 2970-2979.
116. Gerhard A, Pavese N, Hotton G et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 2006; 21: 404-412.
117. Berg D, Godau J, Walter U. Transcranial sonography in movement disorders. Lancet Neurol 2008; 7: 1044-1055.
118. Weise D, Lorenz R, Schliesser M, Schirbel A, Reiners K, Classen J. Substantia nigra echogenicity: A structural correlate of functional impairment of the dopaminergic striatal projection in Parkinson's disease. Mov Disord 2009; 24: 1669-1675.
119. Rascol O, Schelosky L. I-123-metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders. Mov Disord 2009; 24: S732-S741.
120. Burack MA, Hartlein J, Flores HP, Taylor-Reinwald L, Perlmutter JS, Cairns NJ. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology 2010; 74: 77-84.
121. Hong Z, Shi M, Chung KA et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010; 133: 713-726.
122. Mollenhauer B, Trenkwalder C. Neurochemical biomarkers in the differential diagnosis of movement disorders. Mov Disord 2009; 24: 1411-1426.
123. Compta Y, MartíMJ, Ibarretxe-Bilbao N et al. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Mov Disord 2009; 24: 2203-2210.
124. Constantinescu R, Zetterberg H, Holmberg B, Rosengren L. Levels of brain related proteins in cerebrospinal fluid: an aid in the differential diagnosis of parkinsonian disorders. Parkinsonism Relat Disord 2009; 15: 205-212.
125. Eller M, Williams DR. Biological fluid biomarkers in neurodegenerative parkinsonism. Nat Rev Neurol 2009; 5: 561-570.
126. Ravina B, Tanner C, Dieuliis D et al. A longitudinal program for biomarker development in Parkinson's disease: a feasibility study. Mov Disord 2009; 24: 2081-2090.
127. Halliday G, Murphy K. Pathology of Parkinson's disease-an overview. In: Schapira AHV, Lang AET, Fahn S (eds) Movement Disorders 4. Philadelphia: Elsevier Saunders, 2010, pp. 132-154.
128. Beach TG, Adler CH, Sue LI et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 2010; 119: 689-702.
129. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973; 20: 415-455.
130. Porritt MJ, Kingsbury AE, Hughes AJ, Howells DW. Striatal dopaminergic neurons are lost with Parkinson's disease progression. Mov Disord 2006; 21: 2208-2211.
131. Kovacs GG, Milenkovic I, Preusser M, Budka H. Nigral burden of alpha-synuclein correlates with the striatal dopamine deficit. Mov Disord 2008; 23: 1608-1612.
132. Mori F, Nishie M, Kakita A, Yoshimoto M, Takahashi H, Wakabayashi K. Relationship among alpha-synuclein accumulation, dopamine synthesis, and neurodegeneration in Parkinson disease substantia nigra. J Neuropathol Exp Neurol 2006; 65: 808-815.
133. Mori F, Tanji K, Zhang H, Kakita A, Takahashi H, Wakabayashi K. Alpha-Synuclein pathology in the neostriatum in Parkinson's disease. Acta Neuropathol 2008; 115: 453-459.
134. Cabello CR, Thune JJ, Pakkenberg H, Pakkenberg B. Ageing of substantia nigra in humans: cell loss may be compensated by hypertrophy. Neuropathol Appl Neurobiol 2002; 28: 283-291.
135. Rudow G, O'Brien R, Savonenko AV et al. Morphometry of the human substantia nigra in ageing and Parkinson's disease. Acta Neuropathol 2008; 115: 461-470.
136. Rajput AH, Sitte HH, Rajput A, Fenton ME, PiflC, Hornykiewicz O. Globus pallidus dopamine and Parkinson motor subtypes: clinical and brain biochemical correlation. Neurology 2008; 70: 1403-1410.
137. Riederer P, Gerlach M, Müller T, Reichmann H. Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease. Parkinsonism Relat Disord 2007; 13: 466-479.
138. Lee J, Zhu WM, Stanic D et al. Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia. Brain 2008; 131: 1574-1587.
139. Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol 2010; 67: 715-725.
140. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 2009; 8: 382-397.
141. Tansey MG, Goldberg MS. Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 2010; 37: 510-518.
142. Beach TG, Sue LI, Walker DG et al. Marked microglial reaction in normal aging human substantia nigra: correlation with extraneuronal neuromelanin pigment deposits. Acta Neuropathol 2007; 114: 419-424.
143. Knott C, Stern G, Kingsbury A, Welcher AA, Wilkin GP. Elevated glial brain-derived neurotrophic factor in Parkinson's disease nigra. Parkinsonism Relat Disord 2002; 8: 329-341.
144. Chan CS, Gertler TS, Surmeier DJ. A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson's disease. Mov Disord 2010; 25 Suppl 1: S63-S70.
145. Fasano M, Bergamasco B, Lopiano L. Modifications of the iron-neuromelanin system in Parkinson's disease. J Neurochem 2006; 96: 909-916.
146. Braak H, Del Tredici K. Invited Article: Nervous system pathology in sporadic Parkinson disease. Neurology 2008; 70: 1916-1925.
147. Dickson DW, Fujishiro H, DelleDonne A et al. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol 2008; 115: 437-444.
148. Ikemura M, Saito Y, Sengoku R et al. Lewy body pathology involves cutaneous nerves. J Neuropathol Exp Neurol 2008; 67: 945-953.
149. Ghebremedhin E, Del Tredici K, Langston JW, Braak H. Diminished tyrosine hydroxylase immunoreactivity in the cardiac conduction system and myocardium in Parkinson's disease: an anatomical study. Acta Neuropathol 2009; 118: 777-784.
150. Halliday G, Hely M, Reid W, Morris J. The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol 2008; 115: 409-415.
151. Ince PG, Clark B, Holton J, Revesz T, Wharton SB. Disorders of movement and system degenerations. In: Love S, Louis DN, Ellison DW (eds) Greenfield's Neuropathology, 8th ed. London: Hodder Arnold, 2008, pp. 889-1030.
152. Waxman EA, Duda JE, Giasson BI. Characterization of antibodies that selectively detect alpha-synuclein in pathological inclusions. Acta Neuropathol 2008; 116: 37-46.
153. Banerjee R, Starkov AA, Beal MF, Thomas B. Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim Biophys Acta 2009; 1792: 651-663.
154. Dugger BN, Dickson DW. Cell type specific sequestration of choline acetyltransferase and tyrosine hydroxylase within Lewy bodies. Acta Neuropathol 2010; 120: 633-639.
155. Xiong H, Wang D, Chen L et al. Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. J Clin Invest 2009; 119: 650-660.
156. Sulzer D. Clues to how alpha-synuclein damages neurons in Parkinson's disease. Mov Disord 25 Suppl 2010; 1: S27-S31.
157. Leverenz JB, Umar I, Wang Q et al. Proteomic identification of novel proteins in cortical lewy bodies. Brain Pathol 2007; 17: 139-145.
158. Licker V, Dayton L, Turck N et al. Proteomic analysis of the substantia nigra in patients with Parkinson's disease (abs). Mov Disord 2009; 24 (suppl 1): S39.
159. Obi K, Akiyama H, Kondo H et al. Relationship of phosphorylated alpha-synuclein and tau accumulation to Abeta deposition in the cerebral cortex of dementia with Lewy bodies. Exp Neurol 2008; 210: 409-420.
160. Muntané G, Dalfó E, Martinez A, Ferrer I. Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies. Neuroscience 2008; 152: 913-923.
161. Wills J, Jones J, Haggerty T, Duka V, Joyce JN, Sidhu A. Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp Neurol 2010; 225: 210-218.
162. Kuusisto E, Parkkinen L, Alafuzoff I. Morphogenesis of Lewy bodies: dissimilar incorporation of alpha-synuclein, ubiquitin, and p62. J Neuropathol Exp Neurol 2003; 62: 1241-1253.
163. Shehadeh L, Mitsi G, Adi N, Bishopric N, Papapetropoulos S. Expression of Lewy body protein septin 4 in postmortem brain of Parkinson's disease and control subjects. Mov Disord 2009; 24: 204-210.
164. Katsuse O, Iseki E, Marui W, Kosaka K. Developmental stages of cortical Lewy bodies and their relation to axonal transport blockage in brains of patients with dementia with Lewy bodies. J Neurol Sci 2003; 211: 29-35.
165. Power JH, Blumbergs PC. Cellular glutathione peroxidase in human brain: cellular distribution, and its potential role in the degradation of Lewy bodies in Parkinson's disease and dementia with Lewy bodies. Acta Neuropathol 2009; 117: 63-73.
166. Kanazawa T, Uchihara T, Takahashi A, Nakamura A, Orimo S, Mizusawa H. Three-layered structure shared between Lewy bodies and Lewy neurites-three-dimensional reconstruction of triple-labeled sections. Brain Pathol 2008; 18: 415-422.
167. Olszewski J, Baxter D. Cytoarchitecture of the Human Brain Stem. Basel: S. Karger, 1982.
168. Nieuwenhuys R, Voogel J, Van Huizen C. The Human Central Nervous System. A Synopsis and Atlas, 3rd edn. Berlin: Springer, 1988.
169. Ugrumov MV. Non-dopaminergic neurons partly expressing dopaminergic phenotype: distribution in the brain, development and functional significance. J Chem Neuroanat 2009; 38: 241-256.
170. Ubeda-Bañon I, Saiz-Sanchez D, de la Rosa-Prieto C, Argandoña-Palacios L, Garcia-Muñozguren S, Martinez-Marcos A. Alphasynucleinopathy in the human olfactory system in Parkinson's disease: involvement of calcium-binding protein-and substance P-positive cells. Acta Neuropathol 2010; 119: 723-735.
171. Ye L, Velasco A, Fraser G et al. In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. J Neurochem 2008; 105: 1428-1437.
172. Beach TG, Walker DG, Sue LI, Newell A, Adler CC, Joyce JN. Substantia nigra Marinesco bodies are associated with decreased striatal expression of dopaminergic markers. J Neuropathol Exp Neurol 2004; 63: 329-337.
173. Jellinger KA. Basic mechanisms of neurodegeneration: a critical update. J Cell Mol Med 2010; 14: 457-487.
174. Devi L, Raghavendran V, Prabhu BM, Avadhani NG, Anandatheerthavarada HK. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem 2008; 283: 9089-9100.
175. Schapira AH. Etiology and pathogenesis of Parkinson disease. Neurol Clin 2009; 27: 583-603, v.
176. Ferrer I. Early involvement of the cerebral cortex in Parkinson's disease: convergence of multiple metabolic defects. Prog Neurobiol 2009; 88: 89-103.
177. Pan T, Kondo S, Le W, Jankovic J. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain 2008; 131: 1969-1978.
178. Cuervo AM, Wong ES, Martinez-Vicente M. Protein degradation, aggregation, and misfolding. Mov Disord 25 Suppl 2010; 1: S49-S54.
179. Tashiro M, Kojima M, Kihara H et al. Characterization of fibrillation process of alpha-synuclein at the initial stage. Biochem Biophys Res Commun 2008; 369: 910-914.
180. Schulz-Schaeffer WJ. The synaptic pathology of alphasynuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol 2010; 120: 131-143.
181. Alegre-Abarrategui J, Ansorge O, Esiri M, Wade-Martins R. LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease. Neuropathol Appl Neurobiol 2008; 34: 272-283.
182. Fujita Y, Ohama E, Takatama M, Al-Sarraj S, Okamoto K. Fragmentation of Golgi apparatus of nigral neurons with alpha-synuclein-positive inclusions in patients with Parkinson's disease. Acta Neuropathol (Berl) 2006; 112: 261-265.
183. Greffard S, Verny M, Bonnet AM, Seilhean D, Hauw JJ, Duyckaerts C. A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death. Neurobiol Aging 2008; 31: 99-103.
184. Sugeno N, Takeda A, Hasegawa T et al. Serine 129 phosphorylation of alpha-synuclein induces unfolded protein response-mediated cell death. J Biol Chem 2008; 283: 23179-23188.
185. Burke RE, Dauer WT, Vonsattel JP. A critical evaluation of the Braak staging scheme for Parkinson's disease. Ann Neurol 2008; 64: 485-491.
186. Li Y, Liu W, Oo TF et al. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci 2009; 12: 826-828.
187. Brundin P, Melki R, Kopito R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol 2010; 11: 301-307.
188. Mendez I, Viñuela A, Astradsson A et al. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat Med 2008; 14: 507-509.
189. Li JY, Englund E, Widner H et al. Characterization of Lewy body pathology in 12-and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. Mov Disord 2010; 25: 1091-1096.
190. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.
191. Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004; 318: 121-134.
192. Braak H, Del Tredici K. Neuroanatomy and pathology of sporadic Parkinson's disease. Adv Anat Embryol Cell Biol 2009; 201: 1-119.
193. Braak H, Sastre M, Bohl JR, de Vos RA, Del Tredici K. Parkinson's disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre-and postganglionic neurons. Acta Neuropathol 2007; 113: 421-429.
194. Parkkinen L, Pirttilä T, Alafuzoff I. Applicability of current staging/ categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol 2008; 115: 399-407.
195. Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK. Evidence against a reliable staging system of alpha-synuclein pathology in Parkinson's disease. Neuropathol Appl Neurobiol 2009; 35: 125-126.
196. Jellinger KA. A critical evaluation of current staging of alphasynuclein pathology in Lewy body disorders. Biochim Biophys Acta 2009; 1792: 730-740.
197. Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease: a critical analysis of alpha-synuclein staging. Neuropathol Appl Neurobiol 2008; 34: 284-295.
198. Leverenz JB, Hamilton R, Tsuang DW et al. Empiric refinement of the pathologic assessment of lewy-related pathology in the dementia patient. Brain Pathol 2008; 18: 220-224.
199. Zaccai J, Brayne C, McKeith I, Matthews F, Ince PG. Patterns and stages of alpha-synucleinopathy: relevance in a population-based cohort. Neurology 2008; 70: 1042-1048.
200. Beach TG, Adler CH, Lue L et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 2009; 117: 613-634.
201. Kempster PA, O'Sullivan SS, Holton JL, Revesz T, Lees AJ. Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. Brain 2010; 133: 1755-1762.
202. Beach TG, Adler CH, Sue LI et al. Reduced striatal tyrosine hydroxylase in incidental Lewy body disease. Acta Neuropathol 2008; 115: 445-451.
203. Boeve BF, Dickson DW, Olson EJ et al. Insights into REM sleep behavior disorder pathophysiology in brainstem-predominant Lewy body disease. Sleep Med 2007; 8: 60-64.
204. Obeso JA, Marin C, Rodriguez-Oroz C et al. The basal ganglia in Parkinson's disease: current concepts and unexplained observations. Ann Neurol 64 Suppl 2008; 2: S30-S46.
205. Groenewegen HJ, Voorn P, Berendse HW, Mulder AB, Cools AR. The Basal Ganglia IX Advances in Behavioral Biology. Dordrecht, Heidelberg, London, New York: Springer, 2009, p. 608.
206. Reetz K, Gaser C, Klein C et al. Structural findings in the basal ganglia in genetically determined and idiopathic Parkinson's disease. Mov Disord 2009; 24: 99-103.
207. Bagetta V, Ghiglieri V, Sgobio C, Calabresi P, Picconi B. Synaptic dysfunction in Parkinson's disease. Biochem Soc Trans 2010; 38: 493-497.
208. Elias S, Israel Z, Bergman H. Physiology of Parkinson's disease. In: Hallett M, Poewe W (eds) Therapeutics of Parkinson's Disease and Other Movement Disorders. Oxford: Wiley-Blackwell, 2008, pp. 25-36.
209. Deutch AY, Colbran RJ, Winder DJ. Striatal plasticity and medium spiny neuron dendritic remodeling in parkinsonism. Parkinsonism Relat Disord 2007; 3: S251-S258.
210. Calon F, Rajput AH, Hornykiewicz O, Bédard PJ, Di Paolo T. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol Dis 2003; 14: 404-416.
211. Picconi B, PailléV, Ghiglieri V et al. L-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. Neurobiol Dis 2008; 29: 327-335.
212. Volkmann J. Surgery Parkinson's disease. In: Hallett M, Poewe W (eds) Therapeutics of Parkinson's Disease and Other Movement Disorders. Oxford: J. Wiley & Sons, 2008, pp. 120-143.
213. Ni Z, Pinto AD, Lang AE, Chen R. Involvement of the cerebellothalamocortical pathway in Parkinson disease. Ann Neurol 2010; 68: 816-824.
214. Lim SY, Fox SH, Lang AE. Overview of the extranigral aspects of Parkinson disease. Arch Neurol 2009; 66: 167-172.
215. Benarroch EE. The midline and intralaminar thalamic nuclei: anatomic and functional specificity and implications in neurologic disease. Neurology 2008; 71: 944-949.
216. Truong L, Brooks D, Amaral F, Henderson JM, Halliday GM. Relative preservation of thalamic centromedian nucleus in parkinsonian patients with dystonia. Mov Disord 2009; 24: 2128-2135.
217. Gerlach M, Reichmann H, Riederer P. Die Parkinson-Krankheit-Grundlagen, Klinik, Therapie. Vienna: Springer, 2007.
218. Kish SJ, Tong J, Hornykiewicz O et al. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain 2008; 131: 120-131.
219. Rinne JO, Ma SY, Lee MS, Collan Y, Röyttä M. Loss of cholinergic neurons in the pedunculopontine nucleus in Parkinson's disease is related to disability of the patients. Parkinsonism Relat Disord 2008; 14: 553-557.
220. Harding AJ, Stimson E, Henderson JM, Halliday GM. Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain 2002; 125: 2431-2445.
221. Brotchie JM. Pharmacology of Parkinson's disease. In: Hallett M, Poewe W (eds) Therapeutics of Parkinson's Disease and Other Movement Disorders. Oxford: Wiley-Blackwell, 2008, pp. 37-48.
222. Barone P. Neurotransmission in Parkinson's disease: beyond dopamine. Eur J Neurol 2010; 17: 364-376.
223. Tong J, Wong H, Guttman M et al. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation. Brain 2010; 133: 172-188.
224. Braak H, Sastre M, Del Tredici K. Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease. Acta Neuropathol 2007; 114: 231-241.
225. Hornykiewicz O. Chemical neuroanatomy of the basal ganglia-normal and in Parkinson's disease. J Chem Neuroanat 2001; 22: 3-12.
226. Politis M, Wu K, Loane C et al. Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. Neurobiol Dis 2010; 40: 216-221.
227. Pan S, Shi M, Jin J et al. Proteomics identification of proteins in human cortex using multidimensional separations and MALDI tandem mass spectrometer. Mol Cell Proteomics 2007; 6: 1818-1823.
228. Kitsou E, Pan S, Zhang J-P et al. Identification of proteins in human substantia nigra. Proteomics Clin Appl 2008; 2: 776-782.
229. Wenning GK, Stefanova N. Recent developments in multiple system atrophy. J Neurol 2009; 256: 1791-1808.
230. Williams DR, Lees AJ. What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy-parkinsonism (PSP-P)? Mov Disord 2010; 25: 357-362.
231. Ling H, O'Sullivan SS, Holton JL et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain 2010; 133: 2045-2057.
232. McKeith IG, Dickson DW, Lowe J et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863-1872.
233. Dickson DW, Bergeron C, Chin SS et al. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 2002; 61: 935-946.
234. Kalra S, Grosset DG, Benamer HT. Differentiating vascular parkinsonism from idiopathic Parkinson's disease: a systematic review. Mov Disord 2010; 25: 149-156.
235. Kaufmann H, Hague K, Perl D. Accumulation of alpha-synuclein in autonomic nerves in pure autonomic failure. Neurology 2001; 56: 980-981.
236. Tanner CM, Ross GW, Jewell SA et al. Occupation and risk of parkinsonism: a multicenter case-control study. Arch Neurol 2009; 66: 1106-1113.
237. Attems J, Quass M, Jellinger KA. Tau and alpha-synuclein brainstem pathology in Alzheimer disease: relation with extrapyramidal signs. Acta Neuropathol 2007; 113: 53-62.
238. Ponsen MM, Stoffers D, Wolters E, Booij J, Berendse HW. Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson's disease. J Neurol Neurosurg Psychiatry 2010; 81: 396-399.
239. Terzioglu M, Galter D. Parkinson's disease: genetic versus toxininduced rodent models. Febs J 2008; 275: 1384-1391.
240. Tsang AH, Chung KK. Oxidative and nitrosative stress in Parkinson's disease. Biochim Biophys Acta 2009; 1792: 643-650.
241. Martin LJ. Mitochondrial pathobiology in Parkinson's disease and amyotrophic lateral sclerosis. J Alzheimers Dis 20 Suppl 2010; 2: S335-S356.
242. Altamura S, Muckenthaler MU. Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. J Alzheimers Dis 2009; 16: 879-895.
243. McNaught KS, Jackson T, JnoBaptiste R, Kapustin A, Olanow CW. Proteasomal dysfunction in sporadic Parkinson's disease. Neurology 2006; 66: S37-S49.
244. Fasano M, Lopiano L. Alpha-synuclein and Parkinson's disease: a proteomic view. Expert Rev Proteomics 2008; 5: 239-248.
245. Um JW, Park HJ, Song J et al. Formation of parkin aggregates and enhanced PINK1 accumulation during the pathogenesis of Parkinson's disease. Biochem Biophys Res Commun 2010; 393: 824-828.
246. Freestone PS, Chung KK, Guatteo E, Mercuri NB, Nicholson LF, Lipski J. (2009) Acute action of rotenone on nigral dopaminergic neurons-involvement of reactive oxygen species and disruption of Ca homeostasis. Eur J Neurosci 30: 1849-1859.
247. Braak H, Rüb U, Gai WP, Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 2003; 110: 517-536.
248. Lerner A, Bagic A. Olfactory pathogenesis of idiopathic Parkinson disease revisited. Mov Disord 2008; 23: 1076-1084.
249. Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci 2007; 30: 244-250.
250. Hawkes CH, Del Tredici K, Braak H. Parkinson's disease: the dual hit theory revisited. Ann N Y Acad Sci 2009; 1170: 615-622.
251. Schapira AH, Agid Y, Barone P et al. Perspectives on recent advances in the understanding and treatment of Parkinson's disease. Eur J Neurol 2009; 16: 1090-1099.
252. Hallett M, Poewe W (eds) Therapeutics of Parkinson's Disease and Other Movement Disorders. Oxford: Wiley-Blackwell, 2008.
253. Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology 2009; 72: S1-S136.
254. Antonini A, Tolosa E, Mizuno Y, Yamamoto M, Poewe WH. A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet Neurol 2009; 8: 929-937.
255. Hariz MI, Krack P, Alesch F et al. Multicentre European study of thalamic stimulation for parkinsonian tremor: a 6 year follow-up. J Neurol Neurosurg Psychiatry 2008; 79: 694-699.
256. Feng LR, Maguire-Zeiss KA. Gene therapy in Parkinson's disease: rationale and current status. CNS Drugs 2010; 24: 177-192.
257. Olanow CW. Cell-based and gene-based therapy for Parkinson's disease. In: Schapira AHV, Lang AET, Fahn S (eds) Movement Disorders 4. Philadelphia, Saunders-Elsevier, 2010, pp. 286-300.
258. Lo RY, Tanner CM, Albers KB et al. Clinical features in early Parkinson disease and survival. Arch Neurol 2009; 66: 1353-1358.
259. Mylne AQ, Griffiths C, Rooney C, Doyle P. Trends in Parkinson's disease related mortality in England and Wales, 1993-2006. Eur J Neurol 2009; 16: 1010-1016.
260. Driver JA, Kurth T, Buring JE, Gaziano JM, Logroscino G. Parkinson disease and risk of mortality: a prospective comorbidity-matched cohort study. Neurology 2008; 70: 1423-1430.
261. Katzenschlager R, Head J, Schrag A, Ben-Shlomo Y, Evans A, Lees AJ. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 2008; 71: 474-480.
262. Bueler H. Mitochondrial dynamics, cell death and the pathogenesis of Parkinson's disease. Apoptosis 2010; 15: 1336-1353.
263. Aron L, Klein R. Repairing the parkinsonian brain with neurotrophic factors. Trends Neurosci 2011; 34: 88-100.